Stephen Morrissey

Learn More
The governors of a number of states, including New York and New Jersey, recently imposed 21-day quarantines on health care workers returning to the United States from regions of the world where they may have cared for patients with Ebola virus disease. We understand their motivation for this policy — to protect the citizens of their states from contracting(More)
In the first 2 weeks in April, cases of infection with an untypable influenza A virus began to be identified in Mexico and southern California.1 Although the exact sequence of events is uncertain, by the third week of April it was established that the illness resulted from a triple recombination of human, avian, and swine influenza viruses; the virus has(More)
n engl j med 371;15 nejm.org october 9, 2014 1458 proach), we have posted a case at NEJM.org. As the series on fluid and electrolyte disorders goes forward, various cases will be posted 2 weeks before publication of an upcoming review article. These cases will be followed by questions about the diagnosis or management of the condition to be considered in(More)
Clinical studies have become very expensive to conduct, and multiple sources of funding often support a single study. Biomedical journals routinely disclose all sources of funding of the research they publish; this has been standard practice at the Journal for many years. As funding mechanisms grow increasingly complex, however, it has become ever more(More)
We have recently obtained information regarding inaccuracies in data in the report of the VIGOR (Vioxx Gastrointestinal Outcomes Research) study by Bombardier et al.1 that raise concern about certain conclusions in the article. The VIGOR study was designed primarily to compare gastrointestinal events in patients with rheumatoid arthritis randomly assigned(More)
On May 21, 2007, the Journal published a metaanalysis by Nissen and Wolski1 that indicated an increased cardiovascular risk associated with rosiglitazone (Avandia), a thiazolidinedione used to treat type 2 diabetes. We published this analysis because it indicated an increase of about 40% in the risk of myocardial infarction among patients receiving(More)
On September 15, 2010, an advisory committee of the Food and Drug Administration (FDA) will meet to determine the fate of sibutramine, an appetitesuppressant drug that carries the brand name Meridia. This reassessment of sibutramine by the FDA is based on new information derived from the Sibutramine Cardiovascular Outcomes (SCOUT) trial, the results of(More)
n engl j med 358;14 www.nejm.org april 3, 2008 1507 In this issue of the Journal, we publish the results of the Ezetimibe and Simvastatin in Hypercholesterolemia Enhances Atherosclerosis Regression (ENHANCE) trial,1 which addresses the question of whether additional lowering of low-density lipoprotein (LDL) cholesterol with ezetimibe beyond the level(More)